

**MEGASTIGMANE *O*-GLUCOPYRANOSIDES
FROM *Litsea glutinosa***


Yun-Song Wang,¹ Zhen Liao,² Hong-Kun Zhu,³
Xiao-Fei Feng,¹ Kun-Ming-Jiang,¹ Rong Huang,¹
Na Zhu,³ and Jing-Hua Yang^{1*}

UDC 547.972

Litsea glutinosa (Lour.) C. B. Rob., (Lauraceae family) [1] is an evergreen medium-sized tree, which is locally known as “Chan Gao Shu.” Our previous investigation on *L. glutinosa* resulted in the isolation of new aporphine alkaloids and flavone glycoside [2, 3]. In this study, we report the isolation and identification of ten known megastigmane *O*-glucopyranosides **1–10** for the first time from the *n*-BuOH-soluble fraction of an EtOH extract of *L. glutinosa*.

The leaves and twigs of *L. glutinosa* were collected from Xishuangbanna County of Yunnan Province, P. R. China, in October 2002 and identified by Prof. Yu Chen of Kunming Institute of Botany. Powdered materials of *L. glutinosa* (12.0 kg) were repeatedly extracted with EtOH at room temperature. The extract was then concentrated under reduced pressure to give a brown syrup, which was partitioned in H₂O and extracted with solvents into a petroleum ether-fraction (80 g), an EtOAc-fraction (54 g), and an *n*-BuOH-fraction (108 g). The *n*-BuOH-soluble fraction was subjected to silica gel column chromatography eluted with CHCl₃–MeOH (9:1–1:1) and MeOH to afford eight fractions (I–VIII). The resulting fractions were resubmitted to silica gel column chromatography, Sephadex LH-20, and RP-18 to yield compound **1–10**.

The structures of megastigmane *O*-glucopyranosides **1–10** were elucidated on the basis of their MS, ¹H NMR, and ¹³C NMR spectra. All experimental data were in agreement with their IR, UV, 1D, and 2D NMR data in the literature and some were compared with corresponding authentic samples. These megastigmane glycosides are reported for the first time from the genus *Litsea*.



1) Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China, fax: 0871 5035538, e-mail: yangjh@ynu.edu.cn; yangjhkm@hotmail.com; 2) Yunnan Academy of Tobacco Science, Kunming 650031, P. R. China; 3) Yunnan Institute of Product Quality Supervision and Inspection, Kunming 650031, P. R. China. Published in *Khimiya Prirodnikh Soedinenii*, No. 2, March–April, 2012, pp. 310–312. Original article submitted January 12, 2011.

Euodionoside G (1). C₁₉H₃₂O₈, amorphous powder. FAB-MS (Gly, *m/z*, %): 387 ([M – 1]⁻, 100), 325 (30), 265 (8), 225 (35). IR (KBr, ν, cm⁻¹): 3430, 2924, 1655, 1620, 1370, 1075. ¹H NMR (500 MHz, CD₃OD, δ, ppm, J/Hz): 2.55, 2.01 (each 1H, d, J = 17.5, H-2a, 2b), 6.18 (1H, s, H-4), 2.03 (1H, m, H-7), 1.55 (2H, m, H-8), 3.68 (1H, m, H-9), 1.17 (3H, d, J = 6.0, H-10), 1.03 (3H, s, CH₃-11), 1.11 (3H, s, CH₃-12), 4.53, 4.38 (each 1H, dd, J = 1.8, 16.5, CH₃-13), 4.33 (1H, d, J = 7.9, H-1'), 3.26 (1H, m, H-2'), 3.35 (1H, m, H-3'), 3.28 (1H, m, H-4'), 3.28 (1H, m, H-5'), 3.89, 3.67 (each 1H, dd, J = 2.0, 11.8, H-6'). ¹³C NMR (125 MHz, CD₃OD, δ): 37.3 (C-1), 48.8 (C-2), 202.2 (C-3), 123.2 (C-4), 167.9 (C-5), 47.8 (C-6), 27.9 (C-7), 39.7 (C-8), 68.9 (C-9), 23.6 (C-10), 28.9 (C-11), 27.7 (C-12), 70.8 (C-13), 103.5 (C-1'), 75.0 (C-2'), 78.0 (C-3'), 71.6 (C-4'), 78.1 (C-5'), 62.8 (C-6') [4]. The compound was directly compared with authentic samples.

Apocynoside II (2). C₁₉H₃₀O₉, amorphous powder. FAB-MS (Gly, *m/z*, %): 401 ([M – 1]⁻, 100), 325 (4), 265 (2), 221 (12). ¹H NMR (500 MHz, C₅D₅N, δ, ppm, J/Hz): 2.68, 2.39 (each 1H, d, J = 16.7, CH₂-2), 6.95 (1H, s, H-4), 6.28 (1H, d, J = 15.5, H-7), 6.40 (1H, dd, J = 5.4, 15.5, H-8), 4.65 (1H, m, H-9), 1.40 (3H, d, J = 6.4, H-10), 1.08 (3H, s, CH₃-11), 1.21 (3H, s, CH₃-12), 5.25, 4.87 (each 1H, dd, J = 1.9, 17.8, CH₂-13), 4.85 (1H, d, J = 7.7, H-1'), 3.85 (1H, m, H-2'), 4.08 (1H, m, H-3'), 4.25 (1H, m, H-4'), 4.18 (1H, m, H-5'), 4.44, 4.36 (each 1H, dd, J = 2.2, 11.9, H-6'). ¹³C NMR (125 MHz, C₅D₅N, δ): 37.3 (C-1), 48.8 (C-2), 202.2 (C-3), 123.2 (C-4), 167.9 (C-5), 47.8 (C-6), 27.9 (C-7), 39.7 (C-8), 68.9 (C-9), 23.6 (C-10), 28.9 (C-11), 27.7 (C-12), 70.8 (C-13), 103.5 (C-1'), 75.0 (C-2'), 78.0 (C-3'), 71.6 (C-4'), 78.1 (C-5'), 62.8 (C-6') [5]. The compound was directly compared with authentic samples.

Roseoside (3). C₁₉H₃₀O₈, amorphous powder. FAB-MS (Gly, *m/z*, %): 387 ([M + 1]⁺, 70), 225 ([M + H – 163]⁺, 207 (100), 115. ¹H NMR (MeOD, ppm, δ, J/Hz): 5.87 (1H, s, H-5), 5.86, 5.85 (each 1H, overlap, H-7, H-8), 4.41 (1H, m, H-9), 4.33 (1H, d, J = 7.8, Glc-1'), 3.84, 3.63 (each 1H, m, Glc-6'), 2.50, 2.16 (each 1H, d, J = 17.0, H-2), 3.23–3.33 (4H, m, Glc-H), 1.92 (3H, s, CH₃-13), 1.29 (3H, d, J = 6.6, CH₃-10), 1.02, 1.01 (each 3H, s, CH₃-11, 12). ¹³C NMR (MeOD, ppm, δ): 42.4 (C-1), 50.7 (C-2), 201.2 (C-3), 167.3 (C-4), 127.2 (C-5), 80.0 (C-6), 131.5 (C-7), 135.3 (C-8), 77.3 (C-9), 21.2 (C-10), 23.4, 24.7 (C-11, 12), 19.6 (C-13), 102.8 d, 78.1 d, 78.2 d, 75.3 d, 71.7 d, 62.9 (Glc) [6]. The compound was directly compared with authentic samples.

Blumenol C Glucoside (4). C₁₉H₃₂O₇, amorphous powder. FAB-MS (Gly), *m/z* 373 ([M + 1]⁺). ¹H NMR (C₅D₅N, ppm, δ): 5.89 (1H, s, H-5), 2.51, 2.15 (each 1H, d, J = 17.0, H-2), 1.90 (3H, s, CH₃-13), 1.40 (3H, d, J = 6.0, CH₃-10), 0.96, 1.01 (each 3H, s, CH₃-11, 12), 4.93 (1H, d, J = 7.5, H-1'). ¹³C NMR (C₅D₅N, ppm, δ): 36.8 (C-1), 47.7 (C-2), 199.2 (C-3), 125.7 (C-4), 165.2 (C-5), 51.6 (C-6), 25.7 (C-7), 36.5 (C-8), 76.3 (C-9), 21.9 (C-10), 27.4 (C-11), 28.7 (C-12), 24.6 (C-13), 104.3 d, 78.1 d, 78.6 d, 75.3 d, 71.6 d, 62.9 (Glc) [7].

(6R,7E,9R)-9-Hydroxy-megastigma-4,7-dien-3-one 9-O-β-D-glucopyranoside (5). C₁₉H₃₀O₇, amorphous powder. FAB-MS *m/z* 369 [M – H]⁻. ¹H NMR (400 MHz, CD₃OD, δ, ppm, J/Hz): 2.45, 2.05 (each 1H, d, J = 16.4, H-2a, 2b), 5.88 (1H, s, H-4), 2.68 (1H, d, J = 9.0, H-6), 5.67 (1H, dd, J = 9.0, 15.4, H-7), 5.79 (1H, dd, J = 6.4, 15.4, H-8), 4.40 (1H, m, H-9), 1.30 (3H, d, J = 6.4, H-10), 0.99 (3H, s, CH₃-11), 1.05 (3H, s, CH₃-12), 1.93 (3H, CH₃-13), 4.35 (1H, d, J = 7.9, H-1'). ¹³C NMR (100 MHz, CD₃OD, δ): 37.2 (C-1), 48.5 (C-2), 202.3 (C-3), 126.5 (C-4), 166.0 (C-5), 56.9 (C-6), 128.9 (C-7), 138.3 (C-8), 77.2 (C-9), 21.3 (C-10), 27.8 (4C-11), 28.2 (C-12), 24.0 (C-13), 102.5 (C-1'), 75.3 (C-2'), 78.2 (C-3'), 71.6 (C-4'), 77.9 (C-5'), 62.8 (C-6') [8].

Alangionoside E (6). C₁₉H₃₁O₈, amorphous powder. FAB-MS (MNBA) *m/z* 387 ([M – H]⁻). ¹H NMR (500 MHz, CD₃OD, δ, ppm, J/Hz): 1.35 (1H, dd, J = 10, 13, H-2_{ax}), 1.75 (1H, ddd, J = 2, 3, 13, H-2_{eq}), 2.40 (1H, ddd, J = 2, 5, 14, H-4_{eq}), 1.75 (1H, dd, J = 7, 14, H-4_{ax}), 4.30 (1H, m, H-9), 3.90 (1H, m, H-3), 5.65 (1H, dd, J = 6, 16, H-8), 5.93 (1H, dd, J = 1, 16, H-7), 1.24 (3H, d, J = 6.0, H-10), 0.97 (3H, s, CH₃-11), 1.15 (3H, s, CH₃-12), 1.21 (3H, CH₃-13), 4.35 (1H, d, J = 7.8, H-1'), 3.13 (1H, m, H-2'), 3.64 (each 1H, dd, J = 5, 12, H-6'a), 3.85 (1H, dd, J = 2, 12, H-6'b). ¹³C NMR (125 MHz, CD₃OD, δ): 35.7 (C-1), 45.8 (C-2), 73.5 (C-3), 38.3 (C-4), 67.9 (C-5), 71.5 (C-6), 125.9 (C-7), 139.3 (C-8), 68.9 (C-9), 23.6 (C-10), 25.4 (C-11), 29.7 (C-12), 20.4 (C-13), 103.5 (C-1'), 75.0 (C-2'), 77.9 (C-3'), 71.6 (C-4'), 77.9 (C-5'), 62.8 (C-6') [9].

Spinoside A (7). C₁₉H₃₀O₉, amorphous powder. ESI-MS *m/z* 425 ([M + Na]⁺). ¹H NMR (500 MHz, DMSO-d₆, δ, ppm, J/Hz): 2.50, 2.10 (each 1H, d, J = 16.4, H-2), 5.97 (1H, s, H-4), 5.93 (1H, d, J = 15.6, H-7), 5.56 (1H, dd, J = 6.2, 15.6, H-8), 4.41 (1H, m, H-9), 1.15 (3H, d, J = 6.4, H-10), 0.90 (3H, s, CH₃-11), 0.89 (3H, s, CH₃-12), 4.25, 4.01 (each 1H, d, J = 18.6, CH₃-13), 4.09 (1H, d, J = 7.7, H-1'), 2.97 (1H, m, H-2'), 3.07–3.00 (3H, m, H-3', 4', 5'), 3.64 (1H, d, J = 12, H-6'a), 3.43 (1H, dd, J = 4.5, 12, H-6'b). ¹³C NMR (125 MHz, DMSO-d₆, δ): 41.4 (C-1), 49.5 (C-2), 197.5 (C-3), 121.3 (C-4), 167.2 (C-5), 77.3 (C-6), 131.8 (C-7), 131.3 (C-8), 72.1 (C-9), 22.3 (C-10), 23.6 (C-11), 23.1 (C-12), 59.2 (C-13), 100.1 (C-1'), 73.2 (C-2'), 77.0 (C-3'), 70.1 (C-4'), 77.3 (C-5'), 61.2 (C-6') [10]. The compound was directly compared with authentic samples.

Apocynoside I (8). C₁₉H₃₀O₈, amorphous powder. FAB-MS (Gly) *m/z* 386 ([M – 1][–]). ¹H NMR (300 MHz, C₅D₅N, δ, ppm, J/Hz): 2.53, 2.16 (each 1H, d, J = 16.5, CH₂-2), 6.72 (1H, s, H-4), 5.82 (1H, dd, J = 8.9, 15.3, H-7), 5.94 (1H, dd, J = 5.2, 15.4, H-8), 4.55 (1H, m, H-9), 1.40 (3H, d, J = 6.4, H-10), 0.95 (3H, s, CH₃-11), 0.89 (3H, s, CH₃-13), 4.68 (2H, J = 14.9, CH₂-13), 4.85 (1H, d, J = 7.6, H-1'), 3.89 (1H, m, H-2'), 4.13 (1H, m, H-3'), 4.22 (1H, m, H-4'), 4.11 (1H, m, H-5'), 4.44 (2H, m, H-6'). ¹³C NMR (75 MHz, C₅D₅N, δ): 36.3 (C-1), 48.8 (C-2), 198.4 (C-3), 123.6 (C-4), 161.2 (C-5), 51.1 (C-6), 141.3 (C-7), 125.6 (C-8), 62.5 (C-9), 24.6 (C-10), 27.7 (C-11), 27.2 (C-12), 69.2 (C-13), 103.5 (C-1'), 75.1 (C-2'), 78.4 (C-3'), 71.6 (C-4'), 78.2 (C-5'), 62.8 (C-6') [5].

Euodionoside F (9). C₁₉H₃₂O₈, amorphous powder. FAB-MS (Gly), *m/z* 388 ([M – 1][–]). ¹H NMR (500 MHz, CD₃OD, δ, ppm, J/Hz): 6.62 (1H, s, H-4), 4.31, 4.17 (each 1H, dd, J = 1, 18, H-13a, b), 3.81 (1H, m, H-9), 2.57, 2.05 (1H, d, J = 17, H-2a, b), 1.92 (1H, m, H-6), 1.81–1.53 (4H, m, CH₂-7, 8), 1.23 (3H, d, J = 6.0, CH₃-10), 1.01 (3H, s, CH₃-11), 1.12 (3H, s, CH₃-12), 4.33 (1H, d, J = 8, H-1'), 3.84 (1H, m, H-6'a), 3.66 (1H, dd, J = 6, 11, H-6'b), 3.12 (1H, m, H-2'), 3.37–3.28 (3H, m, H-3', 4', 5'). ¹³C NMR (125 MHz, CD₃OD, δ): 37.9 (C-1), 48.9 (C-2), 202.4 (C-3), 121.5 (C-4), 172.3 (C-5), 48.5 (C-6), 27.2 (C-7), 37.4 (C-8), 77.8 (C-9), 21.8 (C-10), 27.8 (C-11), 29.0 (C-12), 65.3 (C-13), 104.1 (C-1'), 75.7 (C-2'), 78.2 (C-3'), 71.7 (C-4'), 77.7 (C-5'), 63.0 (C-6') [4].

Euodionoside A (10). C₁₉H₃₀O₈, amorphous powder. FAB-MS (Gly) *m/z* 385 ([M – 1][–]). ¹H NMR (500 MHz, CD₃OD, δ, ppm, J/Hz): 7.05 (1H, d, J = 16, H-7), 6.21 (1H, d, J = 16, H-8), 2.37 (1H, dd, J = 7, 15, H-4_{eq}), 2.00 (1H, dd, J = 10, 15, H-4_{ax}), 4.00 (1H, m, H-3), 2.30 (3H, s, CH₃-10), 1.25 (3H, s, CH₃-11), 1.18 (3H, s, CH₃-12), 4.31 (1H, d, J = 8, H-1'), 3.13 (1H, dd, J = 8, 9, H-2'), 3.45–3.25 (3H, m, H-3', 4', 5'), 3.88 (1H, dd, J = 2, 12, H-6'a), 3.66 (1H, dd, J = 6, 12, H-6'b). ¹³C NMR (125 MHz, CD₃OD, δ): 35.9 (C-1), 41.3 (C-2), 72.4 (C-3), 38.5 (C-4), 67.3 (C-5), 72.1 (C-6), 143.5 (C-7), 134.4 (C-8), 200.3 (C-9), 27.4 (C-10), 25.1 (C-11), 27.6 (C-12), 21.1 (C-13), 103.1 (C-1'), 75.3 (C-2'), 78.2 (C-3'), 71.8 (C-4'), 78.1 (C-5'), 63.1 (C-6') [4].

Megastigmane and its glycosides are a currently expanding class of compounds. Even with only 13 carbon atoms in the basic skeleton of megastigmane, several oxidation steps and glycosylation afforded many kinds of megastigmane derivatives and their glycosidic forms. Recently, a variety of megastigmane (ionol) glycosides have been isolated from various plant families, including Vitaceae, Apocynaceae, Beridaceae, Staphyleaceae, Rutaceae, Euphorbiaceae, Moraceae, and Cucurbitaceae, and the number of families with this skeleton is increasing [4, 11–14]. Moreover, it seems that the ability to oxidize the megastigmane and its glycosides at C-9 is a common factor, and di-, tri- and tetra-oxygenated megastigmane and its glycosides are often widely distributed in nature. In this study, through a combination of silica gel, RP C-18, and Sephadex LH-20 column chromatography, ten known megastigmane *O*-glucopyranosides **1–10** were isolated for the first time from the traditional Chinese medicine *L. glutinosa* (Lour.) C. B. Rob. All isolated compounds were oxygenated at C-3 and -9 positions. Megastigmane derivatives have, to date, never been reported from the genus *Litsea*. The result of the present study suggests that *L. glutinosa* was a source of megastigmane glycosides. The presence of this class of naturally occurring compounds in the genus *Litsea* could stimulate future phytochemical genomics studies.

ACKNOWLEDGMENT

This work was supported by the National Nature Science Foundation of China (No. 20862018 and 21162038), the Science Foundation of Yunnan University (Grant No. 2009B10Q and X3109007), and the Science Foundation of Yunnan Province (Grants Nos. 2006B0003Q, 2007B0006Z, and 2007PY01-23).

REFERENCES

1. X. W. Li, in: *Delectis Florae Republicae Popularis Sinicae Academiae Sinicae Edita* (Ed.). *Flora Republicae Popularis Sinicae* (in Chinese), tomus **31**, Science Press, Beijing (1982), 285 pp.
2. Y. S. Wang, R. Huang, H. Lu, F. Y. Li, and J. H. Yang, *Biosci. Biotech. Biochem.*, **74**, 652 (2010).
3. J. H. Yang, L. Li, Y. S. Wang, R. Huang, J. F. Zhao, and S. D. Luo, *Helv. Chim. Acta*, **88**, 2523 (2005).
4. M. Yamamoto, T. Akita, Y. Koyama, E. Sueyoshi, K. Matsunami, H. Otsuka, T. Shinzato, A. Takashima, M. Aramoto, and Y. Takeda, *Phytochemistry*, **69**, 1586 (2008).

5. T. Murakami, A. Kishim, H. Matsuda, M. Hattori, and M. Yoshikawa, *Chem. Pharm. Bull.*, **49**, 845 (2001).
6. H. Kuima, H. Otsuka, T. Ide, C. Ogimi, E. Hirata, A. Takushi, and Y. Takeda, *Phytochemistry*, **42**, 723 (1996).
7. M. M. Khaled, H. M. Mahmoud, O. Kazuhiro, K. Ryoji, and Y. Kazuo, *Phytochemistry*, **50**, 859 (1999).
8. K. M. Mohamed, M. H. Mohamed, K. Ohtani, R. Kasai, and K. Yamasaki, *Phytochemistry*, **49**, 748 (1999).
9. H. Otsuka, E. Hirata, T. Shinzato, and Y. Takeda, *Phytochemistry*, **62**, 763 (2003).
10. I. Calis, A. Kuruuzum-Uz, P. A. Lorenzetto, and P. Ruedi, *Phytochemistry*, **59**, 451 (2002).
11. W. S. Feng, H. W. Li, X. K. Zheng, and S. Q. Chen, *Chin. Chem. Lett.*, **18**, 1518 (2007).
12. H. Otsuka, K. Kamada, M. Yao, K. Yuasa, I. Kida, and Y. Takeda, *Phytochemistry*, **38**, 1431 (1995).
13. E. Sueyoshi, H. Liu, K. Matsunami, H. Otsuka, T. Shinzato, M. Aramoto, and Y. Takeda, *Phytochemistry*, **67**, 2483 (2006).
14. Z. Zhang, W. Zhang, Y. P. Ji, Y. Zhao, C. G. Wang, and J. F. Hu, *Phytochemistry*, **71**, 693 (2010).